[go: up one dir, main page]

WO2012045324A8 - Method for detecting a parkinson's disease and test system - Google Patents

Method for detecting a parkinson's disease and test system Download PDF

Info

Publication number
WO2012045324A8
WO2012045324A8 PCT/EP2010/006135 EP2010006135W WO2012045324A8 WO 2012045324 A8 WO2012045324 A8 WO 2012045324A8 EP 2010006135 W EP2010006135 W EP 2010006135W WO 2012045324 A8 WO2012045324 A8 WO 2012045324A8
Authority
WO
WIPO (PCT)
Prior art keywords
sample
parkinson
disease
autoantibody
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/006135
Other languages
French (fr)
Other versions
WO2012045324A1 (en
Inventor
Walter Maetzler
Daniela Berg
Markus Langkamp
Stephanie Hoernig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mediagnost Gesellschaft fur Forschung und Herstellung Von Diagnostika GmbH
Original Assignee
Mediagnost Gesellschaft fur Forschung und Herstellung Von Diagnostika GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediagnost Gesellschaft fur Forschung und Herstellung Von Diagnostika GmbH filed Critical Mediagnost Gesellschaft fur Forschung und Herstellung Von Diagnostika GmbH
Priority to PCT/EP2010/006135 priority Critical patent/WO2012045324A1/en
Publication of WO2012045324A1 publication Critical patent/WO2012045324A1/en
Publication of WO2012045324A8 publication Critical patent/WO2012045324A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3204—Inorganic carriers, supports or substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is directed to a method for detecting a Parkinson's disease (PD) comprising: a) providing an isolated sample which has been taken from an individual, b) determining the presence of at least one autoantibody against a myelin antigen and/of fragment(s) thereof in said isolated sample. The present invention is further directed to a method of monitoring the development and/or the course and/or the treatment of a Parkinson's disease (PD) comprising: a) providing a first sample isolated from an individual at a first time, b) determining the level of at least one autoantibody against a myelin antigen and/or fragment(s) thereof in said first sample, c) providing a second sample isolated from said individual at a second time, d) determining the level of said autoantibody in said second sample, e) comparing the determined level of said autoantibody in said second sample to the level of said autoantibody in said first sample. The present invention is further directed to a test system and an array for performing the method of the invention as well as the use at least one autoantibody against a myelin antigen and/or fragment(s) thereof for detecting a Parkinson's disease (PD).
PCT/EP2010/006135 2010-10-07 2010-10-07 Method for detecting a parkinson's disease and test system Ceased WO2012045324A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/006135 WO2012045324A1 (en) 2010-10-07 2010-10-07 Method for detecting a parkinson's disease and test system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/006135 WO2012045324A1 (en) 2010-10-07 2010-10-07 Method for detecting a parkinson's disease and test system

Publications (2)

Publication Number Publication Date
WO2012045324A1 WO2012045324A1 (en) 2012-04-12
WO2012045324A8 true WO2012045324A8 (en) 2012-08-16

Family

ID=43858490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/006135 Ceased WO2012045324A1 (en) 2010-10-07 2010-10-07 Method for detecting a parkinson's disease and test system

Country Status (1)

Country Link
WO (1) WO2012045324A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
WO2016130793A1 (en) * 2015-02-11 2016-08-18 Rowan University Early stage parkinson's disease diagnostic kits and methods
US20190137490A1 (en) * 2016-05-06 2019-05-09 Duke University Methods and kits for diagnosing and treating nervous system disease or injury

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
JP2002523472A (en) * 1998-08-26 2002-07-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Autoantibody inhibitor
EP1294770B1 (en) * 2000-05-10 2011-12-07 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US20030185815A1 (en) * 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
EP1597557A4 (en) * 2002-10-11 2008-06-11 Univ California METHOD FOR DIAGNOSING AND PROGNOSING MULTIPLE SCLEROSIS
US20070166718A1 (en) * 2004-03-03 2007-07-19 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
US10481167B2 (en) * 2008-12-05 2019-11-19 C2N Diagnostics Methods for measuring concentrations of biomolecules
HUE040281T2 (en) * 2009-09-14 2019-03-28 Banyan Biomarkers Inc Autoantibody markers for diagnosis of traumatic brain injury

Also Published As

Publication number Publication date
WO2012045324A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
WO2007117444A3 (en) Protein detection by aptamers
AU2018260845A1 (en) Evaluation and treatment of bradykinin-mediated disorders
NZ706187A (en) Assays for the detection of anti-tnf drugs and autoantibodies
IL181131A0 (en) USE OF C3a AND DERIVATIVES THEREOF AS A BIOMARKER FOR COLORECTAL ADEMONA AND/OR CARCINOMA; DIAGNOSIS METHOD AND TEST SYSTEM USING THE SAME
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
WO2013093635A3 (en) Plasma micrornas for the detection of early colorectal cancer
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
EP4235181A3 (en) Biomarker detection process and assay of neurological condition
EP2569635A4 (en) METHODS OF DIAGNOSING AND TREATING ENCEPHALITY OR EPILEPSY
DK1991697T3 (en) DNA conformation (LOOP structures) by normal and abnormal gene expression
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
HK1199754A1 (en) Method for monitoring, diagnosis and/or prognosis of acute kidney injury in early stage
WO2012075506A3 (en) Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
HK1206425A1 (en) Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2012096545A3 (en) Novel pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof
HK1259001A1 (en) Methods of prognosis and diagnosis of cancer
HK1232238A1 (en) Novel assay to detect human periostin
WO2015042326A3 (en) Methods for detection and treatment of neurodegenerative diseases
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
WO2010054195A3 (en) Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
WO2012006056A3 (en) Ccr6 as a biomarker of alzheimer's disease
WO2013072060A3 (en) Method for the diagnosis of niemann-pick disease
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2011133036A3 (en) Means and methods for determining risk of cardiovascular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10765966

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 10765966

Country of ref document: EP

Kind code of ref document: A1